Nature Communications (Nov 2021)
Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants
- Sebastian Weigang,
- Jonas Fuchs,
- Gert Zimmer,
- Daniel Schnepf,
- Lisa Kern,
- Julius Beer,
- Hendrik Luxenburger,
- Jakob Ankerhold,
- Valeria Falcone,
- Janine Kemming,
- Maike Hofmann,
- Robert Thimme,
- Christoph Neumann-Haefelin,
- Svenja Ulferts,
- Robert Grosse,
- Daniel Hornuss,
- Yakup Tanriver,
- Siegbert Rieg,
- Dirk Wagner,
- Daniela Huzly,
- Martin Schwemmle,
- Marcus Panning,
- Georg Kochs
Affiliations
- Sebastian Weigang
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Jonas Fuchs
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Gert Zimmer
- Institute of Virology and Immunology, Bern & Mittelhäusern, Switzerland, and Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern
- Daniel Schnepf
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Lisa Kern
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Julius Beer
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Hendrik Luxenburger
- Department of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Jakob Ankerhold
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Valeria Falcone
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Janine Kemming
- Department of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Maike Hofmann
- Department of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Robert Thimme
- Department of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Christoph Neumann-Haefelin
- Department of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Svenja Ulferts
- Institute of Experimental and Clinical Pharmacology and Toxicology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Robert Grosse
- Institute of Experimental and Clinical Pharmacology and Toxicology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Daniel Hornuss
- Division of Infectious Diseases, Dept. Med. II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Yakup Tanriver
- Division of Nephrology, Dept. Med. IV, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Siegbert Rieg
- Division of Infectious Diseases, Dept. Med. II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Dirk Wagner
- Division of Infectious Diseases, Dept. Med. II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Daniela Huzly
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Martin Schwemmle
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Marcus Panning
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- Georg Kochs
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg
- DOI
- https://doi.org/10.1038/s41467-021-26602-3
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 12
Abstract
Here, in a longitudinal case study, Weigang et al. demonstrate that evolution of SARS-CoV-2 within a persistently infected immunosuppressed patient can result in the emergence of novel variants with reduced sensitivity to antibody neutralization.
